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Introduction
Down syndrome (DS) is the most common human dis-
ease caused by a structural chromosome defect, with an
occurrence rate of about 1 in 700 [1,2]. The original
screening test for DS was maternal age or a history of a
previously affected infant. Women who are 35 years or
older account for approximately 30% of DS, which can
be diagnosed mostly by amniocentesis [3,4]. Maternal
serum screening has been incorporated into the rou-
tine prenatal checkup in Taiwan since 1994 [5–8]. Free
β-human chorionic gonadotropin (free β-hCG) and 
α-fetoprotein (AFP) are used as serum markers between
the 15th and 20th week of gestation. The impact of 
second-trimester screening has shown itself by a dra-
matic lowering of the rate of DS live birth from 0.63 to
0.16 per 1,000 live births [7]. Nuchal translucency (NT)
measurement as an approach to DS screening was firstly
reported by Snijders et al [9] in 1998. Furthermore, the
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SUMMARY
Down syndrome (DS) is the most common human disease caused by a structural chromosome defect. The original
screening test for DS was maternal age or a history of a previously affected infant. Maternal serum screening
has been incorporated into routine prenatal checkup in Taiwan since 1994. We used free β-human chorionic
gonadotropin and α-fetoprotein (double test) as the serum markers, and this was carried out between the 15th
to 20th week of gestation. The overall detection rate was 56% and was compatible with studies of Caucasian
populations. The impact of double tests in Taiwan has shown itself by a dramatic lowering of the rate of DS live
birth from 0.63 before screening to 0.16 per 1,000 live births at present. However, because of its relatively low
detection rate and poor cost-effectiveness, the double test is not justified as a routine screening tool currently.
First-trimester combined test is now becoming more widely available and provides increased sensitivity when
detecting DS; it has a detection rate of approximately 85% with a false-positive rate of 5%. Nuchal translucency
measurement requires ongoing quality control and sufficient certificated obstetricians; therefore, first-trimester
ultrasound is limited only in designated centers. The quadruple test, having comparable detection rate, should
be considered for incorporation into second-trimester screening in Taiwan in the near future. Other screening
approaches and combinations have also been utilized in the Western countries. In this review, we outline the
various options with respect to DS screening and hope that this will provide practical information for physicians
offering such screenings. [Taiwan J Obstet Gynecol 2008;47(2):157–162]
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first-trimester combined test, which includes the serum
markers free β-hCG and pregnancy-associated plasma
protein-A (PAPP-A), has reached a detection rate of
nearly 90% [10]. There are many combinations of first-
and second-trimester serum and sonographic screen-
ing tests available at present. The American College 
of Obstetricians and Gynecologists (ACOG) suggests
that first-trimester combined test should be routine for
general population screening [11] and second-trimester
screening should be reserved for when a certificated
sonographer is not available. This article describes the
evolutional changes in DS screening strategies in Taiwan
over the last few years and possible clinical guidelines
for the near future.
Second-trimester Screening
Screening for DS by maternal age started 30 years ago
when amniocentesis was offered only to older women
(those ≥ 35 years old). Second-trimester screening,
generally offered between 14th and 20th week of gesta-
tion, traditionally consists of some combination of
maternal serum analysis and maternal age. In the 1980s,
it was discovered that low maternal serum AFP in the
second trimester was associated with an increased risk
of DS [12–14]. Subsequently, the association between
elevated serum hCG and DS led to the development 
of the “double test”. The double test was introduced
into routine prenatal examinations in Taiwan starting
in 1994 [6]. Tables 1 and 2 show the results for the
double test across the three largest studies carried out
in Taiwan. The detection rate in these studies ranged
from 57% to 63% with a false-positive rate of between
5.3% and 6.5%; these results are compatible with those
obtained from Caucasian population studies [6–8,15].
Later, a third marker for DS, unconjugated estriol, was
found to be lower in affected pregnancies [16]. This
led to the “triple test”, which is commonly used in many
other countries [17]. The overall detection rate using
the triple test increased to 69% with the same false-
positive rate [11]. Recently, inhibin A has been added
to form the “quadruple test”; this has significantly im-
proved screening performance, giving detection rates
that reach 81% with a 5% false-positive rate [10,
15,18]. The quadruple test is currently the most popu-
lar second-trimester screening test in the USA. Wald 
et al [19] suggested that the double test is no longer
justified as a routine screening tool for DS on the basis
of the relatively low detection rates and poor cost-
effectiveness. In Taiwan, we believe that the quadruple
test should be considered for incorporation into second-
trimester screening.
In terms of routine screening in Taiwan, we need to
focus on young mothers. In Taiwan, women with an
advanced age almost always choose genetic diagnosis
[20]. The low cost of genetic diagnosis in Taiwan and
a poor support system for intellectually disabled chil-
dren have resulted in Taiwanese women preferring to
receive amniocentesis rather than risk a DS baby,
despite the fetal loss rate with amniocentesis of nearly
1 in 300. However, if the second-trimester serum test is
offered to the young group only, the overall detection
rate is dramatically decreased. From our unpublished
data, the detection rate of the double test among a
group of women with advanced maternal age was
found to be only 45% with a false-positive rate of 3.0%;
this study was carried out over 7 years from 1999 to
2005 at our institute, the results of which should be
compared with the 46% detection rate from the study
by Wald et al [15]. When the results of three major
studies in Taiwan are correlated, the average detection
rate among women of advanced maternal age is 49%
(Tables 1 and 2).
In Taiwan, over 80% of pregnant women have their
babies delivered in a local hospital or a private clinic,
and therefore, it would be very difficult to train all
obstetricians as qualified sonographers to fully cover
all prenatal services. Furthermore, AFP in the second
trimester could still play a role in detecting neural tube
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Table 1. First- and second-trimester Down syndrome screening tests and detection rates (with a 5% false-positive rate)
Detection rate (%) References
First-trimester NT measurement alone 70 22
First-trimester combined test 82–87 10, 11
Second-trimester double test 57–63 6, 8, 15
Second-trimester triple test 69 15
Second-trimester quadruple test 81 10, 11
Integrated test 94 10, 11
Stepwise sequential test 95 10
Contingent sequential test 88–94 39
NT = nuchal translucency.
defects [11]. Although the detection rate is higher
using the first-trimester combined test, second-trimester
testing would seem to be more convenient and more
reliable for most obstetrics clinics in Taiwan.
First-trimester Screening
First-trimester screening is typically conducted between
the 11th and 14th week of gestation. At this time, NT 
is a powerful sonographic marker for DS, and free 
β-hCG and PAPP-A are the discriminatory serum fac-
tors [9,21,22]. These three markers are used to calcu-
late the likelihood ratio, which is used to modify the
woman’s age-related risk and thus determine the indi-
vidual risk of fetal DS [23]. The performance of NT
screening in terms of success varies among studies,
with the detection rate ranging from 64% to 70% with
a 5% false-positive rate depending on the study [10].
Furthermore, an increased thickness of the NT may
also be associated with other chromosomal abnor-
malities [24–27]. During the early 1990s, several stud-
ies reported the association between DS and a low
level of PAPP-A during the first trimester. A similar
association was found between DS and a high level of
hCG during the first trimester [28,29]. A combination
of NT measurement with the above two serum bio-
chemical markers in the first trimester comprises the
“combined test” [23]. The detection rate for this test
is between 82% and 87% with a false-positive rate of
5%, which is even better than quadruple test in the sec-
ond trimester [10]. The advantage of the combined
test is the availability of the results in the late first
trimester, which allows karyotyping by chorionic villus
sampling and early surgical termination of pregnancy
when this is indicated. The ACOG’s 2007 clinical
guideline concluded that the first-trimester combined
test is an effective screening test for DS for the general
population (level A evidence) [11]. The first-trimester
combined test was introduced at major medical cen-
ters in Taiwan in the beginning of 2006 and was based
on the Fetal Medicine Foundation (FMF) guideline. 
At present, there are 34 FMF certified sonographers 
in our country. The Taiwan Society of Perinatology
announced that the first-trimester combined test ought
to be incorporated into routine care officially. One
study showed that the first-trimester combined test
was the most cost-effective screening tool [30]. We
think that DS screening will move towards first-
trimester testing as a gold standard in the near future
and that this revolutionary change will occur in the
next 10 years. However, the relatively high abortion
rate with chorionic villus sampling and the possibility
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of operator error with sonography should be consid-
ered by clinical doctors. In addition, patients need to
be informed on these facts too.
The FMF at the King’s College Hospital in London
developed the first clinical training program for sonog-
raphers that taught the appropriate technique for
measuring NT. Software for determining the risk assess-
ment of DS using this NT measurement is made avail-
able to those completing the training along with an
ongoing quality assurance system. The results suggest
that this program of training and quality assurance
yields consistently high-quality measurements [31].
Other Soft Markers in the First 
Trimester
Nasal bone
Cicero et al [32] published the first large prospective
trial involving nasal bone assessment in a high-risk
population undergoing chorionic villus sampling to
assess for chromosomal abnormalities. They found
that absence of the nasal bone during first-trimester
scanning was associated with DS. The nasal bone was
absent in 43 of 59 (73%) DS fetuses and in only three
out of 603 (0.5%) euploid fetuses. Based on the high
likelihood ratio for DS with an absent nasal bone and
a similarly low negative likelihood ratio when the nasal
bone was present, this study estimated that nasal
bone assessment would significantly improve the per-
formance of first-trimester ultrasound testing for DS.
Ductus venosus
The ductus venosus is a blood vessel present during
embryonic and fetal life that originates from the
umbilical vein and empties into the inferior vena cava
just proximal to its entry into the right atrium. The
normal Doppler waveform of the ductus venosus is
pulsatile and should always demonstrate forward
flow. However, reversed flow has been associated with
both aneuploidy and congenital heart disease [33].
Tricuspid regurgitation
In 2003, Huggon et al [34] reported the relationship
between tricuspid regurgitation and aneuploidy in
women referred for early fetal echocardiography.
Abnormal karyotypes were found in 83% of fetuses
with tricuspid regurgitation. To date, only a few stud-
ies linking tricuspid regurgitation with DS have been
published. Further investigations in this area may
prove productive. Like ductus venosus, measuring the
standard tricuspid regurgitation needs to be performed
by a well-trained sonographer.
First- Plus Second-trimester Screening
The integrated test
The integrated test combines first-trimester NT meas-
urement and serum PAPP-A levels with second-trimester
AFP, β-hCG, unconjugated estriol and inhibin A (the
quadruple test) [15]. In an initial report, the estimated
detection rate for the integrated test was 94%. The
major advantage of this test is its high detection rate,
which implies that fewer women will need to undergo
invasive testing with the inherent risk of miscarriage
using the integrated test; and equally importantly, fewer
women will be made anxious about their pregnancy
[35]. The integrated test has been challenged ethically,
since the integration of first- and second-trimester
markers in a single test could pose a problem with
respect to the withholding of first-trimester result,
thus denying the mother the possible advantages of 
an earlier pregnancy termination [36]. Another major 
disadvantage is the relatively high cost. As a population-
based screening tool, the cost would be very high if 
all women received both first- and second-trimester
testing.
The sequential test
Sequential testing involves the performance of both
first- and second-trimester testing, but with the imme-
diate disclosure of first-trimester results for use in clini-
cal management. There are three approaches to such
sequential risk management: (1) independent, (2)
stepwise, and (3) contingent.
1. Independent sequential testing involves the inde-
pendent interpretation of first-trimester combined
test and second-trimester serum test. The first-
trimester result is given to the patient for clinical
decision-making. The second-trimester test is inter-
preted without taking into account the first-
trimester results, i.e. maternal age is used as the 
a priori risk for the second-trimester testing. Although
the sensitivity is high, this is the least efficient risk
assessment strategy, because the test’s additive
false-positive rate is unacceptably high [10,37].
2. Stepwise sequential testing suggests an early inva-
sive procedure if the first-trimester result is above 
a specific cut-off. If the first-trimester risk assess-
ment result is below this cut-off, then the patient 
is offered second-trimester testing, with the final
risk being determined using all the markers. A
detection rate of 95% with a 4.9% false-positive
rate has been shown [10]. The advantage of this
approach is sensitivity and a false-positive rate
approaching that obtained using integrated risk
assessment, but with the option that the early
Taiwan J Obstet Gynecol • June 2008 • Vol 47 • No 2160
S.W. Shaw, et al
results are available in the first trimester for the
highest-risk patients.
3. Contingent sequential testing begins with the per-
formance of first-trimester risk assessment. On the
basis of these results, women are grouped into one
of three risk categories: high-risk, intermediate-risk,
and low-risk. The cut-off points of the groups and
their specific risks vary, depending upon how these
groups are defined [38]. For contingent sequential
risk assessment to be successful, careful determina-
tion of the risk cut-offs is required. The first-trimester
cut-off must identify a significant proportion of 
DS pregnancies with only a small number of false-
positives. In one study, the detection rate was 88–94%
with a 5% false-positive rate [39]. Of all the potential
screening protocols, contingent sequential screen-
ing seems to have the most advantages. It should
achieve a high detection rate with a very low false-
positive rate. Most importantly, the majority of
women would have their screening completed in the
first trimester, which will substantially reduce patient
anxiety and increase test satisfaction. Patients would
benefit from both first- and second-trimester screen-
ing, yet the obstetricians would not have to hold
back information or wait until the second trimester
to disclose the test results. Thus, this protocol is
highly likely to increase physician satisfaction as well.
Multiple Pregnancies
Multiple pregnancy is another topic that is associated
with serum screening. A recent consensus is that first-
trimester NT measurement is superior to second-
trimester screening [40]. All monochorionic pregnancies
are monozygotic; however, not all dichorionic preg-
nancies are dizygotic. The risk of DS for each fetus is
independent in dizygotic twin pregnancies. This indi-
cates that for dichorionic twin pregnancies, the preg-
nancy specific risk needs to be calculated by summing
the individual risk estimates for each fetus [41]. On
the contrary, the risk would be based on the average 
of likelihood ratios derived from nuchal measure-
ments of both twins in monochorionic pregnancies.
Therefore, diagnosis of chorionicity should be the first
step in ultrasound evaluation of twins during the first
trimester.
Current Strategies and Conclusion
We had offered the second-trimester double test for over
14 years and then started to set up a first-trimester
platform 2 years ago. Pregnant women in Taiwan now
have a choice in terms of DS screening, namely first- or
second-trimester screening. The cost of first-trimester
DS screening is about twice that of second-trimester
DS screening. However, the detection rate of double
test is only about 50%. Doctors in obstetrics across
Taiwan should offer a better screening tool in the sec-
ond trimester, namely triple or quadruple test, and
replace the double test. Clinical physicians with certifi-
cation for first-trimester nuchal scanning are able to
provide first-trimester screening during early preg-
nancy or in cases of high-risk pregnancy with an obvi-
ous family history. Nonetheless, for those doctors
without certification or those in rural areas, a more
effective second-trimester screening is essential. The
detection rate of the quadruple test is comparable
with that of the first-trimester combined test. If the
first-trimester combined test and the second-trimester
quadruple test were popularly available in Taiwan and
an official consensus announced by the Taiwan
Society of Perinatology, the live birth rate of DS babies
in Taiwan would decrease even further to an all-time
low very quickly.
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